Price$1.13+0.28 (+32.94%)
2026-02-272026-06-02
News · 26 weeks16-100%
2025-12-072026-05-31
Mix990d
- Insider6(67%)
- Other2(22%)
- SEC Filings1(11%)
Latest news
25 items- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash FlowThe Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for 2025. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2025 Financial Highlights and Milest
- SECSEC Form 20-F filed by Intercure Ltd.20-F - Intercure Ltd. (0001857030) (Filer)
- INSIDERSEC Form 3 filed by new insider Rabinovich Alexander3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Michelson Lennie Grinbaum3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Granot Alon Shmuel3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Salton David3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen Amos3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hirschfeld Gideon3 - Intercure Ltd. (0001857030) (Issuer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Receives Nasdaq Notification Regarding Minimum Bid RequirementNEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requir
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 MillionInterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts ar
- PRInterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 MillionInterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts are
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical InnovationAgreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) ("InterCure" or the "Company") today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. ("Cannasoul"), a globally recognized pioneer in cannabis research and analytics
- PRInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash FlowThe Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLIYA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for the first half of 2025. Al
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and BrandsAcquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the strategic acquisition of Botanico Ltd., also
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 20252024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility. InterCure received NIS 62 million until December 31, 2024 (to date, NIS 82 million) as partial advanced payments from the Israeli authorities and expects to receive additional substantial payments.Revenues in 2024 reached NIS 239 million, alongside an Adjusted EBITDA[1] of NIS 24 million (approximately 10% of revenues).InterCure announced expansion of its strategic partnership with Cookies™ to Germany and expec
INCR FAQ
6 questionsWhat does Intercure Ltd. do?
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Where does INCR stock trade?
Intercure Ltd. (INCR) is listed on NASDAQ.What sector and industry is INCR in?
Intercure Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INCR?
Intercure Ltd. has had 1 recent analyst action on file. The most recent action was from Canaccord Genuity: Buy with a $1300.00 price target on 2022-05-18. Recent price targets cluster around $1300.00.What companies are similar to INCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INCR side-by-side with any of them on Quantisnow.How can I track INCR on Quantisnow?
Quantisnow aggregates Intercure Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCR to receive live email and push alerts on every new disclosure.